Regulus Announces Pricing of Initial Public Offering

             Regulus Announces Pricing of Initial Public Offering

PR Newswire

LA JOLLA, Calif., Oct. 4, 2012

LA JOLLA, Calif., Oct. 4, 2012 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
pricing of its initial public offering of 11,250,000 shares of its common
stock at $4.00 per share. Regulus has also granted the underwriters a 30-day
option to purchase up to an additional 1,687,500 shares at the initial public
offering price to cover overallotments, if any. Regulus' common stock is
scheduled to begin trading on The NASDAQ Global Market on October 4, 2012
under the symbol "RGLS."

Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets are
acting as joint book-running managers for the offering. Needham & Company and
Wedbush PacGrow Life Sciences are acting as co-managers.

A registration statement relating to these securities was declared effective
by the Securities and Exchange Commission on October 4, 2012.

The offering is being made only by means of a prospectus, copies of which may
be obtained from Lazard Capital Markets LLC, Attn: Syndicate Department, 30
Rockefeller Plaza, 48th Floor, New York, NY 10020, Telephone: (800) 542-0970;
from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Telephone:
(631) 274-2806, Fax: 631-254-7140); or from BMO Capital Markets, Attention:
Equity Syndicate Department, 3 Times Square New York, NY 10036, Telephone:
(800) 414-3627, E-mail: bmoprospectus@bmo.com.

This press release shall not constitute an offer to sell or a solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About Regulus

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), is a biopharmaceutical
company leading the discovery and development of innovative medicines
targeting microRNAs. Regulus is using a mature therapeutic platform based on
technology that has been developed over 20 years. Regulus is advancing
microRNA therapeutics toward clinical development in several areas, including
oncology, fibrosis, hepatitis C and metabolic diseases.







SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: David Schull, Russo Partners LLC, +1-212-845-4271,
david.schull@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.